41 year old male came with a history of PTCA 11 years back. Currently he is asymptomatic. His 2decho showed EF 40%, LV DYSFUNCTION, LV RWMA. His LDL is 98 , tsh is 6 . He is on dapaglifazolin 10, metaprolol 25 plus ramipril 2.5 . Im planning to change metaprolol ramipril combination to sacubitril plus valsartan, change dapaglifazolin plain to dapaglifazolin plus bisoprolol and add Aldactone. Also asked him to check nt pro bnp
Reading File
Finding Sources
Finding Sources
Searching PubMed
sacubitril valsartan HFrEF asymptomatic LV dysfunction
Searching PubMed
SGLT2 inhibitor bisoprolol combination heart failure
Reading File
Finding Sources
Finding Sources
Searching PubMed
heart failure reduced ejection fraction GDMT guideline 2024
Reading File
Finding Sources
Finding Sources
Searching the Web
2022 AHA ACC heart failure guidelines HFrEF GDMT quadruple therapy sacubitril valsartan SGLT2 asymptomatic
Now I have everything I need. Let me give a thorough, structured clinical response.
Clinical Review: 41M, Post-PTCA 11 Years, EF 40%, Asymptomatic - Proposed Regimen Analysis
This patient has HFrEF (EF 40%), LV dysfunction with RWMA, post-PTCA - an ischemic cardiomyopathy etiology. He is currently NYHA Class I (asymptomatic). Let me go through each proposed change systematically.
1. OVERALL FRAMEWORK: Is This HFrEF or HFimpEF?
This is a critical classification point. Per the 2022 AHA/ACC/HFSA HF Guidelines:
- HFrEF = LVEF ≤40% (this patient qualifies with EF 40%)
- HFimpEF = prior LVEF ≤40% that has now improved to >40%
Since this is his current EF and he was never formally diagnosed with HF previously (asymptomatic post-PTCA), he is best classified as HFrEF with NYHA Class I symptoms - which means all four pillars of GDMT apply. The guidelines explicitly recommend continuing/initiating GDMT even in asymptomatic patients to prevent progression.
2. CHANGE: Metoprolol + Ramipril → Sacubitril/Valsartan (ARNI)
This is an excellent and guideline-directed decision. Here is the evidence and practical protocol:
Evidence:
- PARADIGM-HF trial (n=8,442, HFrEF EF ≤40%, NYHA II-IV): Sacubitril/valsartan vs. enalapril reduced the composite of CV death or HF hospitalization by 20%, all-cause mortality, and sudden cardiac death by 22% (HR 0.78)
- The 2022 AHA/ACC/HFSA guidelines give sacubitril/valsartan Class I, Level A recommendation as preferred RASi over ACEi/ARB in HFrEF
Critical transition protocol - do NOT miss this:
⚠️ Mandatory 36-hour washout after stopping ramipril before starting sacubitril/valsartan. ACEi + ARNI combination causes angioedema risk due to concurrent neprilysin inhibition and bradykinin accumulation. This washout is non-negotiable.
Practical steps:
- Stop ramipril
- Wait minimum 36 hours (some centers use 48h to be safe)
- Start sacubitril/valsartan at 24/26 mg twice daily (starting dose)
- Titrate every 2-4 weeks to target 97/103 mg twice daily as tolerated
- Monitor BP, renal function, and potassium at each titration step
On the beta-blocker: You are switching from metoprolol succinate to bisoprolol (bundled in the dapagliflozin combination). That is fine - only three beta-blockers have mortality benefit in HFrEF: carvedilol, metoprolol succinate (CR/XL), and bisoprolol. All three are acceptable; bisoprolol is guideline-endorsed.
- Bisoprolol starting dose: 1.25 mg once daily, target 10 mg once daily
- Ensure the fixed-dose dapagliflozin/bisoprolol combination delivers the correct bisoprolol dose and allows titration - fixed combinations may limit dose flexibility, which is a practical concern worth flagging
3. CHANGE: Dapagliflozin (plain) → Dapagliflozin + Bisoprolol (fixed combination)
Dapagliflozin 10 mg is already appropriately chosen - DAPA-HF trial showed 26% relative risk reduction in worsening HF events or CV mortality in chronic HFrEF, irrespective of diabetes status. This is a Class I recommendation in the 2022 guidelines.
Practical concern with fixed combination:
- Fixed-dose combinations are convenient for adherence
- However, bisoprolol requires up-titration from a starting dose to target over weeks. A fixed combination locks both doses together, potentially limiting independent titration
- If the fixed combination is available at multiple dose strengths (e.g., dapagliflozin 10mg + bisoprolol 2.5/5/10mg), this works well
- Confirm that bisoprolol in the combination is being started at a low dose given no prior bisoprolol use
4. ADD: Spironolactone (Aldactone)
Strongly supported. MRA is the third pillar of GDMT for HFrEF.
- RALES trial: spironolactone reduced all-cause mortality by 30% in severe HF
- EMPHASIS-HF (eplerenone): benefit extended to NYHA Class II (mild symptoms)
- 2022 guidelines: MRA is Class I, Level A for NYHA Class II-IV HFrEF if eGFR >30 mL/min/1.73m² and K+ <5.0 mEq/L
Dosing:
- Start spironolactone 25 mg once daily
- Can uptitrate to 50 mg/day if tolerated
- Alternative: eplerenone (avoids gynecomastia in a 41-year-old male - worth considering)
⚠️ Key monitoring before adding Aldactone in this combination:
- Since the patient will also be on sacubitril/valsartan (valsartan component blocks RAAS) + ramipril being stopped: hyperkalemia risk is significant with triple RAAS-like effect
- Check baseline K+, eGFR, creatinine before initiation
- Recheck at 1 week, 4 weeks after starting
- Target K+ <5.0 mEq/L; stop if K+ >5.5 mEq/L
5. NT-proBNP CHECK - Appropriate and Important
Excellent decision. Key reasons:
- Sacubitril inhibits neprilysin - which breaks down BNP. Therefore, BNP levels rise spuriously after starting sacubitril/valsartan, making BNP unreliable for monitoring
- NT-proBNP is NOT a neprilysin substrate - it remains a reliable biomarker even on ARNI therapy
- This NT-proBNP serves as a baseline before starting sacubitril/valsartan, allowing you to track response over time
- Also helps risk-stratify: very high NT-proBNP at baseline despite asymptomatic status could indicate occult congestion
6. TSH 6 - SUBCLINICAL HYPOTHYROIDISM: Action Needed
TSH of 6 mIU/L = subclinical hypothyroidism (SCH). This has specific implications for this patient:
- Subclinical hypothyroidism can worsen LV dysfunction and contribute to heart failure
- It impairs cardiac contractility, increases LDL, and may blunt response to GDMT
- In a patient with HFrEF, treating SCH to restore euthyroid state may actually improve EF
- Current evidence suggests treatment is reasonable in SCH when TSH is 5-10 mIU/L, especially with cardiovascular disease
Recommended action:
- Check free T4 and anti-TPO antibodies (to assess autoimmune thyroiditis)
- If free T4 is low-normal and anti-TPO positive, start levothyroxine 25-50 mcg/day
- Start at a very low dose given cardiac disease - higher doses can precipitate angina or arrhythmia
- Recheck TSH in 6-8 weeks; target TSH 0.5-2.5
7. LDL 98 mg/dL - NEEDS ATTENTION
This patient has established ASCVD (post-PTCA = history of coronary artery disease). The 2022 ACC/AHA guidelines for secondary prevention mandate:
- LDL target: <55 mg/dL (very high risk: known ASCVD with multiple risk factors, especially with heart failure)
- Some guidelines use <70 mg/dL as the minimum target, but most current guidelines push to <55 mg/dL for high-intensity statin therapy in ASCVD + HFrEF
LDL of 98 is significantly above target. Is he on a statin? This is not mentioned in the current drug list. If not:
- Start high-intensity statin: rosuvastatin 20-40 mg or atorvastatin 40-80 mg
- If already on a statin and LDL is 98, consider adding ezetimibe 10 mg or escalating statin dose
- Consider PCSK9 inhibitor if target still not reached
8. SUMMARY TABLE OF PROPOSED CHANGES
| Change | Evidence Base | Guideline Class | Practical Concern |
|---|---|---|---|
| ACEi → ARNI (sacubitril/valsartan) | PARADIGM-HF | Class I-A (preferred) | 36h washout mandatory |
| Metoprolol → Bisoprolol | Comparable Class I-A agents | Class I-A | Fixed-dose titration flexibility |
| Add Aldactone (spironolactone) | RALES, EMPHASIS-HF | Class I-A | Monitor K+, eGFR closely |
| Dapagliflozin continued at 10mg | DAPA-HF | Class I-A | No change needed |
| NT-proBNP baseline check | Guideline-supported | Standard practice | BNP unreliable on ARNI |
| TSH 6 - treat SCH | Cardiovascular evidence | Reasonable in HFrEF | Start levo at low dose |
| LDL 98 - intensify statin | ASCVD secondary prevention | Class I | Target <55 mg/dL |
9. FINAL PROPOSED REGIMEN (Revised/Complete)
| Drug | Dose | Purpose |
|---|---|---|
| Sacubitril/valsartan | Start 24/26 mg BD, uptitrate to 97/103 mg BD | ARNI - pillar 1 |
| Bisoprolol (or via fixed combination) | Start 1.25-2.5 mg OD, target 10 mg OD | Beta-blocker - pillar 2 |
| Spironolactone | 25 mg OD (uptitrate to 50) | MRA - pillar 3 |
| Dapagliflozin | 10 mg OD | SGLT2i - pillar 4 |
| High-intensity statin | Rosuvastatin 20-40 mg or Atorvastatin 40-80 mg | LDL <55 mg/dL (ASCVD) |
| Levothyroxine | 25 mcg OD (uptitrate) | Treat SCH, may improve EF |
10. MONITORING PLAN
- At 1 week: BP (watch for hypotension on ARNI + SGLT2i), renal function, K+ (hyperkalemia risk with spironolactone + ARNI)
- At 1 month: Repeat K+, creatinine, eGFR; titrate beta-blocker
- At 3 months: Repeat 2D echo to reassess EF response, NT-proBNP, thyroid function after levothyroxine
- At 6 months: Lipid panel to reassess LDL; continue ARNI titration
- Ongoing: Annual echo, NT-proBNP trend, NYHA class reassessment
This is a well-thought-out and largely guideline-congruent plan. The major additions I would flag are: the mandatory 36-hour ACEi washout, treating the TSH, and aggressively targeting the LDL.
What about glp analogue. He is non diabetic
Searching PubMed
GLP-1 receptor agonist heart failure reduced ejection fraction non-diabetic
Searching the Web
semaglutide GLP-1 agonist HFrEF non-diabetic 2024 2025 clinical trial evidence guidelines
Finding Sources
Reading Web Page
GLP-1 agonist semaglutide HFrEF safety risk non-diabetic
Searching PubMed
GLP-1 receptor agonist HFrEF hospitalization risk liraglutide semaglutide FIGHT LIVE trial
Excellent - now I have very precise and current data to answer this well.
GLP-1 Receptor Agonists in This Patient: A Nuanced Answer
The Short Answer
Do NOT add a GLP-1 RA routinely to this patient's regimen. The evidence in HFrEF specifically suggests potential harm (increased HF hospitalizations), not benefit - and this is independent of diabetes status. This is one of the most clinically important distinctions in cardiology right now.
The Evidence Breakdown: HFpEF vs HFrEF - Completely Different Stories
In HFpEF (obesity-related) - GLP-1 RAs work well:
- STEP-HFpEF trial (non-diabetic patients): Semaglutide improved KCCQ scores, 6-minute walk distance, weight, and reduced CRP
- SELECT trial (17,604 non-diabetic obese patients with CVD): Semaglutide reduced the composite of CV death + atherosclerotic events by 20%; HF hospitalizations reduced by ~40% in the HFpEF subgroup
In HFrEF - the signal is worrying:
| Trial | Drug | Finding in HFrEF |
|---|---|---|
| FIGHT | Liraglutide | Trend toward more HF hospitalizations and adverse cardiac events |
| LIVE | Liraglutide | More serious cardiac adverse events in liraglutide arm vs placebo despite modest 6MWT improvement |
| EXSCEL | Exenatide | Increased HF events in patients with LVEF ≤40% |
| SELECT (HFrEF subgroup) | Semaglutide | Reduced CV/all-cause mortality, but did NOT reduce HF hospitalizations in the HFrEF subgroup - neutral at best |
A meta-analysis of FIGHT + EXSCEL (n=769 HFrEF patients) showed GLP-1 RAs increased HF hospitalization risk by 49% (OR 1.49; 95% CI 1.05-2.10; p=0.02) - a statistically significant harm signal.
A 2025 meta-analysis in JACC Heart Failure (Neves et al., JACC HF 2025;13:102489) of RCTs of GLP-1 RAs specifically in HFrEF confirmed this concerning pattern.
Why Does This Paradox Exist?
Several proposed mechanisms:
- Increased heart rate - GLP-1 RAs raise resting HR by 5-10 bpm; in a failing heart already compensating with tachycardia, this may worsen hemodynamics
- Sympathomimetic effects - GLP-1 receptors are expressed in the cardiac conduction system; stimulation increases sympathetic tone, which is counterproductive in HFrEF where you are trying to reduce it (hence beta-blockers)
- Fluid retention - Some GLP-1 RAs may promote sodium retention at higher doses
- Counteraction of beneficial neurohormonal suppression - The core of HFrEF management is RAAS + sympathetic blockade; GLP-1 RAs may partially undo this
What About the SELECT HFrEF Subgroup?
The authors of the JACC editorial (Neves et al., 2024) make an important methodological point: patients labeled as HFrEF in SELECT likely did NOT have true established HFrEF. They probably had CAD with mild/asymptomatic systolic impairment or recovered EF - which is actually very similar to your patient (post-PTCA, asymptomatic, EF 40% at the borderline). So the SELECT data cannot be extrapolated to justify GLP-1 RA use in true chronic HFrEF.
Applying This to Your Patient
| Factor | Comment |
|---|---|
| EF 40%, HFrEF | GLP-1 RA not indicated; HF hospitalization risk signal |
| Non-diabetic | No metabolic indication |
| Post-PTCA, ischemic cardiomyopathy | GDMT quadruple therapy is the priority |
| Asymptomatic | Optimize the four pillars first |
| If BMI >30 (obese) | There may be a role after complete GDMT optimization; use with caution and monitor closely |
| If BMI normal | No indication whatsoever |
Bottom Line Recommendation
- Do not add a GLP-1 RA to this patient's current regimen
- His GDMT (ARNI + beta-blocker + MRA + SGLT2i) is the proven quadruple therapy with mortality benefit in HFrEF
- GLP-1 RAs are not part of HFrEF GDMT in any current guideline (2022 AHA/ACC/HFSA or 2023 ESC)
- The space where GLP-1 RAs shine is obesity-driven HFpEF - a very different phenotype
- If his BMI is significantly elevated and EF improves with GDMT to >40% (HFimpEF), you could revisit this discussion at a later date
The addition of a GLP-1 RA in this specific patient would be going against the evidence grain - the SGLT2i (dapagliflozin) already covers the cardiorenal protection you want, without the heart rate and sympathetic activation concerns of GLP-1 RAs.
This is a shared conversation. Sign in to Orris to start your own chat.